The development of robust clinical trial methodologies increasingly relies on advanced statistical frameworks for model selection and the characterisation of dose–response relationships. With modern ...
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...
Risankizumab (Skyrizi), a selective anti-interleukin-23 (IL-23) biologic agent, is increasingly used in the treatment of Crohn's disease (CD). A previous head-to-head study has demonstrated its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback